— Know what they know.
Not Investment Advice
Also trades as: PME.AX (ASX) · $vol 31M

PMCUF OTC

Pro Medicus Limited
1W: -5.0% 1M: -11.9% 3M: -23.2% YTD: -24.9% 1Y: -46.2% 3Y: +112.7% 5Y: +164.8%
$108.86
-5.19 (-4.55%)
 
Weekly Expected Move ±4.7%
$99 $104 $109 $114 $119
OTC · Healthcare · Medical - Healthcare Information Services · Tech Score Sell · Power 40 · $11.4B mcap · 53M float · 0.0007% daily turnover · Short 53% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$11.4B
52W Range74.52-209.99
Volume300
Avg Volume369
Beta0.57
Dividend$0.49
Analyst Ratings
No analyst coverage
Company Info
CEOSam Aaron Hupert
Employees153
SectorHealthcare
IndustryMedical - Healthcare Information Services
IPO Date2021-01-08
450 Swan Street
Richmond, VIC 3121
AU
61 3 9429 8800
About Pro Medicus Limited

Based in Richmond, Australia, and established in 1983, Pro Medicus Limited is a leading developer and provider of cutting-edge healthcare imaging software and support services. The company caters to a diverse range of medical institutions, including hospitals and diagnostic imaging facilities, across Australia, North America, and Europe. Its comprehensive product suite features a proprietary Radiology Information System (RIS), designed for efficient practice management, which comes complete with training, installation, professional services, and ongoing post-sales support (marketed under names like Visage RIS). Additionally, Pro Medicus offers Promedicus.net, an e-health platform, and advanced healthcare imaging software that empowers radiologists and clinicians with robust visualization capabilities for 2D, 3D, and 4D medical images, alongside its Picture Archiving and Communication System (PACS)/digital imaging solutions (e.g., Visage 7). The company also provides integration products and the Visage Ease Pro mobile application, allowing users to remotely interpret diagnostic imaging studies stored on a Visage 7 server.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms